首页> 外文期刊>Lung cancer: Journal of the International Association for the Study of Lung Cancer >CT-planned accelerated hypofractionated radiotherapy in the radical treatment of non-small cell lung cancer.
【24h】

CT-planned accelerated hypofractionated radiotherapy in the radical treatment of non-small cell lung cancer.

机译:CT计划的加速超分割放疗在非小细胞肺癌的根治性治疗中。

获取原文
获取原文并翻译 | 示例
           

摘要

Surgery is the standard treatment for stage I, II and certain stage IIIA non-small cell lung cancers (NSCLC). A proportion of patients with technically operable NSCLC do not undergo surgery because of significant co-morbidity or refusal, and radical radiotherapy may cure some of these patients. Between April 1997 and March 2000, 135 consecutive patients with stage I-IIIB NSCLC were treated with CT-planned accelerated hypofractionated radical radiotherapy to a dose of 50-55Gy in 15-20 fractions over 3-4 weeks at a single centre. The 2-year overall and cause-specific survival for all patients was 44.4% (95% CI = 36.8, 53.7) and 47.8% (95% CI = 39.9, 57.3) respectively. Overall median survival was 21 months (95% 18, 28). There were no reports of severe acute or late treatment-related toxicities. These results compare favourably with previously published studies on radical radiotherapy in NSCLC, suggesting this may be an effective and safe technique.
机译:手术是I,II期和某些IIIA期非小细胞肺癌(NSCLC)的标准治疗方法。由于明显的合并症或拒绝,有一部分技术上可行的非小细胞肺癌患者不接受手术,根治性放疗可以治愈其中一些患者。在1997年4月至2000年3月之间,连续135个I-IIIB期NSCLC患者接受了CT计划的加速超分割根治性放射治疗,在一个中心进行了3-4周的15-20次分次剂量为50-55Gy的治疗。所有患者的2年总体生存率和特定原因生存率分别为44.4%(95%CI = 36.8,53.7)和47.8%(95%CI = 39.9,57.3)。总体中位生存期为21个月(95%18、28)。没有关于严重急性或晚期治疗相关毒性的报道。这些结果与先前发表的关于NSCLC根治性放射治疗的研究相比具有优势,表明这可能是一种有效且安全的技术。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号